T-CURX GmbH has secured $20 million in funding to enhance the development of accessible CAR-T therapies for cancer, driven by an international investor consortium.

Target Overview

T-CURX GmbH, based in Würzburg, Germany, specializes in developing advanced and accessible CAR-T therapies for cancer treatment. With a recent funding round securing $20 million (approximately €17.7 million) from an international consortium of investors led by Swiss firm BiomedVC, T-CURX aims to accelerate the development of non-viral CAR-T therapies targeting acute myeloid leukemia (AML) and solid tumors. The company also focuses on proprietary technologies to produce CAR-T cells directly within the body, making these innovative cancer treatments more efficient and cost-effective for a broader patient population.

Founded in 2017 as a spinoff from the University Hospital of Würzburg and led by Professor Michael Hudecek, chair of Cellular Immunotherapy, T-CURX is dedicated to making CAR-T cell therapies more affordable and widely available. The CAR-T cell therapy approach has been recognized as one of the most effective treatments for cancer, altering a patient's T-cells to recognize and combat tumor cells effectively.

Industry Overview in Germany

The biopharmaceutical industry in Germany is known for its robust research capabilities and innovation in the field of life sciences, particularly in cancer treatments. The country is home to a growing number of biotech startups that focus o